TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04812964

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass
Description: Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate
Description: High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
Study: NCT01801891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VASGARD stimulator
Description: The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandaging
Description: Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandaging
Description: Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
Study: NCT00594438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes Reamer-Irrigator-Aspirator (RIA)
Description: A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer Sentinel Reamer
Description: A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
Study: NCT03846596

Intervention type: BIOLOGICAL
Intervention: Additional blood tube
Description: Additional blood tube during care
Study: NCT02185833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYNABAC 250 MG ENTERIC COATED TABLET
Study: NCT02259868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS /1B, current low dose formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS /1B, current low dose formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS /1B, current low dose formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS /1B, current high dose formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Suspension low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS - Suspension high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT02557451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injections of an antiangiogenic
Study: NCT00193128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
Study: NCT01601990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group(once daily)
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444 50mg qd
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
Study: NCT03128255

Intervention type: OTHER
Intervention: Assessment of already preacquired I-124 PET/US
Description: Assessment of preacquired I-124 PET/US by review of anonymous digital case files
Study: NCT03351062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Description: Patients will be given 60mg Toremifene once a day.
Study: NCT04507516

Intervention type: OTHER
Intervention: Water-only Fasting
Description: Water-only fasting for at least 10 days followed by 5 days of refeed.
Study: NCT03336281

Intervention type: DRUG
Intervention: Ustekinumab
Description: All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.

Intervention type: DRUG
Intervention: Ustekinumab
Description: All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
Study: NCT01454609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal saline
Description: Saline
Study: NCT03583489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: 10 mg IV
Study: NCT01454609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine (combination)
Description: Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg
Study: NCT00296465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsatile gonadotropin-releasing hormone (GnRH)
Description: Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsatile gonadotropin-releasing hormone (GnRH)
Description: Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsatile gonadotropin-releasing hormone (GnRH)
Description: Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Oral clomiphene citrate (over encapsulated) for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Oral clomiphene citrate (over encapsulated) for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pulsatile GnRH
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pulsatile GnRH
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pulsatile GnRH
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pulsatile GnRH
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Clomiphene Citrate
Description: oral placebo clomiphene citrate for 5 days
Study: NCT03960060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-59
Description: Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
Study: NCT01624961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
Study: NCT04404790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg +0.002 IU/kg/h
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg +0.004 IU/kg/h
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 5 IU/60kg +0.008 IU/kg/h
Description: 5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg +0.002 IU/kg/h
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg +0.004 IU/kg/h
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide 7 IU/60kg +0.008 IU/kg/h
Description: 7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
Study: NCT05223023

Intervention type: OTHER
Intervention: questionnaire
Description: All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training
Study: NCT02570724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of HES  Voluven® 
Description: Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood patch
Study: NCT01523743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact
Description: The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The coated intermittent catheter normally used by subject
Study: NCT01062724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primene 10 % from Baxter
Description: Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
Study: NCT00956137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: ultrasound imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual palpation
Description: Manual Palpation of vertebra
Study: NCT01389453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell transplantation
Description: Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
Study: NCT00203918

Intervention type: BEHAVIORAL
Intervention: Survey, interview
Description: A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
Study: NCT03583489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: 10 mg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4 mg IV
Study: NCT03490097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 10mg
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir plus daclatasvir
Description: sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir plus daclatasvir
Description: sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
Study: NCT02804932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g/day) for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Super Beets Placebo
Description: Nitrate deficient beetroot powder (10g/day) for 8 weeks
Study: NCT01693653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Intravenous infusions every 4 weeks for 3 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Intravenous infusions every 4 weeks for 3 doses.
Study: NCT00203918

Intervention type: BEHAVIORAL
Intervention: patient utility scores (i.e. patient preference weights)
Description: comparison of patient preferences
Study: NCT01878838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
Description: Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser
Description: Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
Study: NCT02085317

Intervention type: DRUG
Group type: OTHER
Intervention: acetylcholine Iontophoresis
Description: Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.

Intervention type: DRUG
Group type: OTHER
Intervention: acetylcholine Iontophoresis
Description: Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.

Intervention type: DRUG
Group type: OTHER
Intervention: sodium nitroprusside Iontophoresis
Description: After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.

Intervention type: DRUG
Group type: OTHER
Intervention: sodium nitroprusside Iontophoresis
Description: After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.